We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.00 | 9.00 | 9.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.34 | 52.55M |
TIDMETX
RNS Number : 3275R
e-Therapeutics plc
26 October 2023
e-therapeutics plc
("e-therapeutics" or "ETX" or the "Company")
Interim results for the six months to 31 July 2023
Six months of progress with positive proof-of-concept data generated with lead GalOmic (TM) RNAi assets in cardiometabolic disease and haemophilia
Continued integration of generative artificial intelligence into HepNet (TM)
London, UK, 26 October 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces its unaudited interim results for the six months to 31 July 2023.
Operational Highlights
á Continued growth and rapid advancement of GalOmic (TM) RNAi therapeutics against target genes discovered using our HepNet (TM) computational platform, including preclinical programs in cardiometabolic and metabolic disease, haemophilia, and two further undisclosed programs.
á Generated positive proof-of-concept data for ETX-291 in cardiometabolic disease and ETX-148 in haemophilia, demonstrating disease-modifying potential of HepNet (TM) identified targets.
á Increased pool of novel targets identified and assessed in silico by HepNet (TM) , ensuring a continual supply of in-house preclinical programs and a variety of partnering opportunities spanning a broad range of therapeutic areas.
á C ontinued validation of HepNet (TM) , including our hepatocyte-specific knowledge graph, proprietary target identification approaches, and siRNA (short interfering RNA) construct design capabilities.
á Advanced projects developing and implementing generative artificial intelligence ("AI") including large language models ("LLMs") across ETX processes and systems, further enhancing computational capabilities, and transforming HepNet (TM) into a dynamic knowledge resource.
á Continued expansion of AI approaches, enabling the transformation of siRNA construct design and selection to reduce timelines and associated costs dramatically.
á Sustained intellectual property ("IP") activity continued, with priority forming patent applications filed on three new inventions, and consolidated international filing programs for eight inventions, all arising from the Company's proprietary GalNAc-siRNA technology, GalOmic (TM) .
á Strong progress made in immuno-oncology collaboration with iTeos Therapeutics, Inc. ("iTeos"), with continued delivery against pre-agreed milestones.
Post Period Highlights
á Effective 20 September 2023, Timothy Bretherton assumed the role of Chief Financial Officer (non-board). Michael Bretherton stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company.
Financial Highlights
á Revenue of GBP0.2 million (H1 2022: GBP0.3 million) á R&D spend of GBP5.3 million (H1 2022: GBP3.1 million) á Operating loss for the period of GBP7.0 million (H1 2022 loss: GBP4.6 million) á Loss after tax for the period of GBP5.6 million (H1 2022 loss: GBP3.8 million)
á Cash and cash equivalents as at 31 July 2023 of GBP24.8 million (31 January 2023: GBP31.7 million)
á R&D tax credit receivable as at 31 July 2023 of GBP2.5 million (31 January 2023: GBP1.5 million)
á Headcount (excluding Non-Executive Directors) as at 31 July 2023 of 34 (31 January 2023: 38)
Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:
"Despite a severe macroeconomic climate, we have made significant progress during the past six months. It is a tribute to our team that we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor. We look forward to showcasing additional data from our preclinical pipeline in the near future.
"It has only been six months since we began incorporating generative AI into our processes and projects, but the significant impact of these technologies throughout ETX is already apparent. Through this work, we continue to address directly the long, expensive, and risky product lifecycle of drug discovery, solidifying ourselves as one of the leading companies in the emerging TechBio sector. A year ago, generative AI technologies did not exist. Now, we are integrating them into every aspect of our drug development process, allowing us to develop our life-transforming RNAi medicines at pace. As we continue to leverage the most cutting-edge computation, I look forward to the future with confidence."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.
e-therapeutics plc Ali Mortazavi, CEO Tel: +44 (0)1993 883 Timothy Bretherton, CFO 125 www.etherapeutics.co.uk ------------------------------------------------ ------------------------- SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470 Nominated Adviser and Broker Matthew Johnson/Harry Davies-Ball (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) ------------------------------------------------ -------------------------
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.
ETX's proprietary HepNet (TM) platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises, and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.
GalOmic (TM) , ETX's proprietary RNAi platform, enables targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNet (TM) . The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmic (TM) constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, haemophilia, and other undisclosed indications . ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.
Chief Executive's Statement
During the past six months, we have concluded the successful transition into a proven RNAi biotech company. Our lead assets in cardiometabolic disease and haemophilia have progressed to preclinical proof-of-concept experiments, validating our HepNet (TM) computational platform, our GalOmic (TM) chemistry platform, and delivering proof in support of our goal of Computing the Future of Medicine (TM) .
While we continue to build our in-house pipeline of assets, we are progressing HepNet (TM) into the central nexus within e-therapeutics. By leveraging generative artificial intelligence ("AI") and large language model ("LLM") advances, we have built on the validated technology and data resources in HepNet-- and are beginning to unlock next-level predictive power in a truly seamless system. This transformation will continue to deliver novel therapeutics at an unprecedented scale, increasing the pace of target identification and dramatically reducing the time and cost of developing life-transforming medicines.
GalOmic (TM) RNAi Platform and Continued Execution of Therapeutic Pipeline
We continue to progress our therapeutic pipeline, with five assets currently in preclinical studies across a range of therapeutic areas, including cardiometabolic disease and haemophilia. During the past six months, we have generated positive proof-of-concept data for ETX-291 in cardiometabolic disease and ETX-148 in haemophilia, underscoring the robustness of the GalOmic (TM) platform and validating HepNet (TM) 's ability to identify novel genes with therapeutic potential. These proof-of-concept data are underpinned by the silencing profile of our siRNA platform. GalOmic (TM) constructs have demonstrated potent and durable knockdown of target mRNA expression of therapeutically relevant targets in vivo, supporting infrequent dosing.
ETX-291 for the Treatment of Cardiometabolic Disease
Cardiometabolic diseases are a leading cause of death and encompass multiple conditions including obesity, cardiovascular disease, and Type 2 diabetes. ETX-291 targets a gene with human genetic evidence of disease-modifying benefit. In preclinical studies in a representative disease model, ETX-291 impacts multiple cardiometabolic disease drivers resulting in a pleiotropic benefit and highlighting its potential to treat a broad range of cardiometabolic indications.
ETX-148 for the Treatment of Haemophilia
ETX-148 is our preclinical pan-haemophilia asset. We have generated data that suggests it is safe, effective, and able to address a key remaining unmet need in haemophilia: protection from joint bleeds. Histological data from a preclinical joint bleed model suggests ETX-148 can protect against bleed-induced joint damage. Importantly, this protection is achieved without an increased risk of thrombosis, which has been characterised in a variety of safety experiments.
ETX-291 and ETX-148 are due to complete preclinical proof-of-concept studies by the end of the year and we are looking forward to presenting further details of our preclinical data packages in the near future. Additionally, we continue to add to our pool of novel targets, ensuring our early pipeline is populated and generating additional partnering opportunities.
Non-dilutive funding opportunities via collaborations and partnerships remain a key component of the Company's strategy. Successfully demonstrating preclinical proof-of-concept for our first RNAi assets is fuelling partnering and out-licensing conversations both for individual assets and platform access, striking a balance between preclinical assets to partner and assets that we will progress to early clinical trials to reach a more significant value inflection point.
HepNet-- and Integration of Large Language Models
We continue to strengthen, innovate, and validate HepNet (TM) , the most comprehensive hepatocyte data and analytics resource in the world. This has included the generation of positive proof-of-concept data for our in-house GalOmic (TM) pipeline programs, validating HepNet (TM)' s ability to reliably identify novel gene targets and design potent siRNA constructs. Furthermore, we have continued to expand our knowledgebase, initiating partnerships that will provide access to proprietary data assets that will support disease-related process and target discovery.
We are fully embracing generative AI and LLMs by creating specialised LLM "agents" and transforming HepNet (TM) into a dynamic knowledge resource. Over the past six months, this ambitious agenda has driven design and development of infrastructure and model development and refinement. Over the coming months it will deliver a unifying framework driving every aspect of our pipeline, solidifying e-therapeutics' position as a global leader in AI-driven drug development.
Our projects include our "Straight to In Vivo" efforts, which will allow us to bypass in vitro screening and move straight to in vivo models. This will dramatically reduce timelines and costs associated with identifying optimal siRNA constructs to silence any hepatocyte-expressed target gene. We ultimately aim to create a robust pipeline and business model leveraging the full potential of Generative AI and LLM to continue breaking new ground in drug discovery, creating novel therapeutics, and improving patient outcomes.
Intellectual Property
The Company continues to execute its very active IP strategy that is indicative of both the high volume of novel innovations being generated and the critical importance ETX attributes to protecting its inventions. The patent applications filed over the period 31 January 2023 to 31 July 2023 cover eleven inventions arising from the Company's innovation around novel target ideas, novel siRNA therapeutics, and novel siRNA chemistries.
Partnerships and Collaborations
We continue to deliver on our collaboration with iTeos Therapeutics, leveraging our unique computational methodology to enable the discovery of highly differentiated novel immuno-oncology therapeutics. The work is progressing well against pre-defined plans and milestones, successfully passing decision gates. As well as receiving near-term cash payments material to the revenue of the Company, we are eligible to receive undisclosed milestone payments through preclinical and clinical development, in addition to regulatory milestones, per programme.
Organisation
ETX continues to invest in and attract leading industry talent, adding to an existing world class multi-disciplinary team of experts in computational biology and RNAi therapeutics. This is exemplified by our recent hires in the USA, driven by our desire to hire the best talent and resulting in a lean presence on the East Coast, a major biotech hub.
The team has worked hard to deliver the progress highlighted in this statement and I should like to thank them for their continued commitment and dedication in helping ETX to deliver on its strategy and key objectives.
At a Board level, there is an open position for an additional independent NED to broaden the Board experience further and adhere to best practice corporate governance guidelines.
Post Period
On 20 September 2023, ETX announced that Michael Bretherton had stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, assumed the CFO role (non-board) with immediate effect.
Outlook
Despite a severe macroeconomic climate, we have made significant progress during the past six months. It is a tribute to our team that we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor. We look forward to showcasing additional data from our preclinical pipeline in the near future.
It has only been six months since we began incorporating generative AI into our processes and projects, but the significant impact of these technologies throughout ETX is already apparent. Through this work, we continue to address directly the long, expensive, and risky product lifecycle of drug discovery, solidifying ourselves as one of the leading companies in the emerging TechBio sector. A year ago, generative AI technologies did not exist. Now, we are integrating them into every aspect of our drug development process, allowing us to develop our life-transforming RNAi medicines at pace. As we continue to leverage the most cutting-edge computation, I look forward to the future with confidence.
Ali Mortazavi
Chief Executive Officer
Financial Review
Period end cash of GBP24.8m and operating loss of GBP7.0m in H1, FY2024.
The Company continues to manage the underlying cash burn carefully whilst focusing on the development of ETX engineered large language models ("LLMs") to enhance and expand our computational capabilities leading to development of multiple preclinical assets across a variety of therapeutic areas with unmet medical needs.
Revenue
The Company reached another milestone with iTeos in May this year, resulting in the recognition of GBP0.2 million of revenue (H1 2022: GBP0.3 million including remaining Galapagos milestone). This collaboration is focusing on the discovery of novel therapeutic approaches and targets in immuno-oncology. The last phase of this project is underway and is expected to be completed during Q1 of FY2025.
Research and Development
R&D expenditure in H1 2023 increased to GBP5.3 million (H1 2022: GBP3.1 million). This mainly reflects an increase in outsourced CRO costs to progress the execution of preclinical targets, together with additional cost in relation to our computational and RNAi platforms and associated patent applications. Through increased expenditure, we have made compelling advancements in our goal of Computing the Future of Medicine (TM) .
During H2, we are expecting a further increase in R&D costs as we continue to focus on the development of our LLMs, alongside progressing the execution of preclinical targets and growing our in-house pipelines across a variety of therapeutic areas.
General and Administrative Expenses
General and administrative expenses have remained broadly in-line with the prior half year and amounted to GBP1.8 million (H1 2022: GBP1.7 million). We continue to monitor and control these costs closely to ensure maximum cash availability for R&D expenditure to help us accomplish our mission to discover life-transforming RNAi medicines.
R&D tax credits and loss for the half year
The income statement includes an R&D tax credit of GBP1.0 million (H1 2022: GBP0.7 million) in relation to the current year, bringing down the loss after tax for the half year to GBP5.6 million (H1 2022: GBP3.8 million). The increase in tax credit from the prior half year reflects the increase in qualifying R&D spend in the period.
Cash flow
Cash as at 31 July 2023 stood at GBP24.8 million, which is GBP6.8 million lower than the start of the year. The reduction reflects an operating cash outflow of GBP6.6 million, net of non-cash share-based employee option charges, depreciation and amortisation, coupled with working capital outflows of GBP0.2 million, property lease liability payments of GBP0.2 million and purchase additions of GBP0.1 million to fixed and intangible assets, partially offset by interest income receipts of GBP0.3 million. Cash balances are expected to benefit by a cash receipt of GBP1.5 million in the last quarter of the current financial year in respect of the R&D tax credit relating to FY2023.
Financial Outlook
Our current expectations for the underlying cash burn in the second half of the financial year will be higher than that incurred in H1 2023. This is due to our planned increase in R&D spend to continue the expansion of our AI capabilities and progress the identification and execution of preclinical targets, together with sustaining our active IP strategy as novel inventions are generated.
INCOME STATEMENT FOR THE PERIODED 31 JULY 2023 --------------------------------------------------------------------------------------------------- 6 months 6 months ended ended 31 Year ended 31 July 2023 July 2022 31 January 2023 (un audited) (un audited) (audited) GBP'000 GBP'000 GBP'000 Revenue 160 295 475 Cost of sales - - - -------------------------------------- ---------------- -------------------- ------------------- Gross profit 160 295 475 Research and development expenditure (5,324) (3,123) (7,224) Administrative expenses (1,806) (1,727) (3,490) -------------------------------------- ---------------- -------------------- ------------------- Operating loss (6,970) (4,555) (10,239) Interest income 343 46 490 Interest expense (4) (12) (23) -------------------------------------- ---------------- -------------------- ------------------- Loss before tax (6,631) (4,521) (9,772) Taxation 1,037 709 1,498 -------------------------------------- ---------------- -------------------- ------------------- Loss for the period/year attributable to equity holders of the Company (5,594) (3,812) (8,274) -------------------------------------- ---------------- -------------------- ------------------- Loss per share: basic and diluted (0.97)p (0.74)p (1.54)p -------------------------------------- ---------------- -------------------- ------------------- STATEMENT OF COMPREHENSIVE INCOME FOR THE SIX MONTHSED 31 JULY 2023 ----------------------------------------------------------------------------------- Year ended 6 months ended 6 months ended 31 January 31 July 2023 31 July 2022 2023 (un audited) (un audited) (audited) GBP'000 GBP'000 GBP'000 Loss for the period (5,594) (3,812) (8,274) Other comprehensive income - - - --------------------------------- ---------------- ---------------- ------------ Total comprehensive income for the period/year attributable to equity holders of the Company (5,594) (3,812) (8,274) --------------------------------- ---------------- ---------------- ------------ STATEMENT OF CHANGES IN EQUITY FOR THE PERIODED 31 JULY 2023 ---------------------------------------------------------------------------------------------- Share capital Share Retained premium earnings Total GBP'000 GBP'000 GBP'000 GBP'000 As at 1 February 2022 515 99,243 (72,032) 27,726 Total comprehensive income for the period Loss for the period - - (3,812) (3,812) ---------------------------------------- ---------------- ------------- ---------- ------- Total comprehensive income for the period - - (3,812) (3,812) Transactions with owners, recorded directly in equity Issue of ordinary shares - 8 - 8 Equity-settled share-based payment transactions - - 196 196 ---------------------------------------- ---------------- ------------- ---------- ------- Total contributions by and distribution to owners - 8 196 204 ---------------------------------------- ---------------- ------------- ---------- ------- As at 31 July 2022 515 99,251 (75,648) 24,118 Total comprehensive income for the period Loss for the period - - (4,462) (4,462) ---------------------------------------- ---------------- ------------- ---------- ------- Total comprehensive income for the period (4,462) (4,462) Transactions with owners, recorded directly in equity Issue of ordinary shares 67 13,362 - 13,429 Equity-settled share-based payment transactions - - (41) (41) ---------------------------------------- ---------------- ------------- ---------- ------- Total contributions by and distribution to owners 67 13,362 (41) 13,388 ---------------------------------------- ---------------- ------------- ---------- ------- As at 31 January 2023 582 112,613 (80,151) 33,044 Total comprehensive income for the period Loss for the period - - (5,594) (5,594) ---------------------------------------- ---------------- ------------- ---------- ------- Total comprehensive income for the period - - (5,594) (5,594) Transactions with owners, recorded directly in equity Issue of ordinary shares 1 21 - 22 Equity-settled share-based payment transactions - - 59 59 ---------------------------------------- ---------------- ------------- ---------- ------- Total contributions by and distribution to owners 1 21 59 81 ---------------------------------------- ---------------- ------------- ---------- ------- As at 31 July 2023 583 112,634 (85,686) 27,531 ---------------------------------------- ---------------- ------------- ---------- ------- STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2023 ------------------------------------------------------------------------------------- 31 July 31 July 31 January 2023 2022 2023 Note (un audited) (un audited) (audited) GBP'000 GBP'000 GBP'000 Non-current assets Intangible assets 301 182 239 Property, plant and equipment 175 617 400 ------------------------------ --- ------------------- ------------- ------------ 476 799 639 ------------------------------ --- ------------------- ------------- ------------ Current assets Tax receivable 2,537 2,184 1,500 Trade and other receivables 302 192 259 Prepayments 647 563 553 Cash and cash equivalents 24,845 21,561 31,689 28,331 24,500 34,001 ------------------------------ --- ------------------- ------------- ------------ Total assets 28,807 25,299 34,640 ------------------------------ --- ------------------- ------------- ------------ Current liabilities Trade and other payables 1,186 687 1,301 Lease Liability 90 405 295 Contract liabilities - - - ------------------------------ --- ------------------- ------------- ------------ 1,276 1,092 1,596 ------------------------------ --- ------------------- ------------- ------------ Non-current liabilities
Lease Liability - 89 - ------------------------------ --- ------------------- ------------- ------------ Total liabilities 1,276 1,181 1,596 ------------------------------ --- ------------------- ------------- ------------ Net assets 27,531 24,118 33,044 ------------------------------ --- ------------------- ------------- ------------ Equity Share capital 2 583 515 582 Share premium 112,634 99,251 112,613 Retained earnings (85,686) (75,648) (80,151) ------------------------------ --- ------------------- ------------- ------------ Total equity attributable to equity holders of the Company 27,531 24,118 33,044 ------------------------------ --- ------------------- ------------- ------------ CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 JULY 2023 6 months ended 6 months ended Year ended 31 July 31 July 31 January 2023 2022 2023 (un audited) (un audited) (audited) GBP'000 GBP'000 GBP'000 Loss for the period/year (5,594) (3,812) (8,274) Adjustments for: Depreciation, amortisation and impairment 271 242 468 Loss on disposal of fixed assets - - 10 Interest income (343) (46) (490) Interest expense 4 12 23 Equity-settled share-based payment expenses 59 196 155 Taxation (1,037) (709) (1,522) -------------------------------------------- ------------ ---------------- ------------ Operating cash flows before movements in working capital (6,640) (4,117) (9,630) (Increase)/Decrease in trade and other receivables (137) (19) (75) Increase/(Decrease) in trade and other payables (110) (608) 198 Tax received - - 1,496 -------------------------------------------- ------------ ---------------- ------------ Net cash from operating activities (6,887) (4,744) (8,011) -------------------------------------------- ------------ ---------------- ------------ Interest received 343 46 490 Interest paid (4) (12) (23) Acquisition of property, plant and equipment (5) (51) (68) Acquisition of other intangible assets (103) (83) (142) Movement in short term investments - 15,051 15,051 -------------------------------------------- ------------ ---------------- ------------ Net cash from investing activities 231 14,951 15,308 -------------------------------------------- ------------ ---------------- ------------ Net proceeds from issue of share capital 22 8 13,437 Payments under lease liabilities - - - Repayment of lease liability (210) - (391) -------------------------------------------- ------------ ---------------- ------------ Net cash from financing activities (188) 8 13,046 -------------------------------------------- ------------ ---------------- ------------ Net decrease in cash and cash equivalents (6,844) 10,215 20,343 Cash and cash equivalents at the beginning of the period/year 31,689 11,346 11,346 -------------------------------------------- ------------ ---------------- ------------ Cash and cash equivalents at the end of the period/year 24,845 21,561 31,689 -------------------------------------------- ------------ ---------------- ------------
Notes
1. Basis of Preparation
These unaudited interim financial statements do not comprise statutory accounts as defined within section 434 of the Companies Act 2006. The Company is a public limited company; it is listed on the London Stock Exchange's AIM market and is incorporated and domiciled in the United Kingdom. The address of its registered office is 4 Kingdom Street, Paddington, London, W2 6BD, UK.
Statutory accounts for the year ended 31 January 2023 were approved by the Board of Directors on 4 May 2023 and delivered to the Registrar of Companies. The report of the Auditor on the accounts was unqualified, did not contain an emphasis of matter paragraph and did not contain any statement under section 498 of the Companies Act 2006.
While this interim statement, which is neither audited nor reviewed, has been prepared in accordance with the recognition and measurement criteria of international accounting standards in conformity with the requirements of the Companies Act 2006 this announcement does not in itself contain sufficient information to comply with IFRS. It does not include all the information required for the full annual financial statements and should be read in conjunction with the financial statements as at, and for the year ended, 31 January 2023. It does not comply with International Accounting Standard ("IAS") 34 'Interim Financial Reporting' as is permissible under the rules of AIM.
The accounting policies applied in preparing these interim financial statements are the same as those applied in the preparation of the annual financial statements for the year ended 31 January 2023 (as defined therein) other than standards, amendments and interpretations which became effective after
1 February 2023.
New standards, amendments and interpretations not adopted in the current financial year have not been disclosed as they are not expected to have a material impact on the Company's financial statements.
2. Share Capital 31 July 2023 31 July 2022 31 January 2023 (unaudited) (un audited) (audited) ------------------ ----------------------- --------------------- In issue - fully paid Ordinary shares of GBP0.001 each (number) 582,694,162 514,614,982 582,159,332 -------------------------------- ------------------ ----------------------- --------------------- Allotted, called up and fully paid Ordinary shares of GBP0.001 each (GBP'000) 583 515 582 -------------------------------- ------------------ ----------------------- ---------------------
During the six-month period to 31 July 2023, 500,000 new ordinary shares of 0.1p each were issued following the exercise of share options at a price of 2.8p per share by a former employee and 34,830 new ordinary shares of 0.1p each were issued at a price of 21.71p each in lieu of fees payable to a non-executive director in accordance with his service agreement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR PPGRUUUPWPWA
(END) Dow Jones Newswires
October 26, 2023 02:38 ET (06:38 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions